Yahoo Web Search

Search results

  1. Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

  2. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling. This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only.

  3. pro.novonordisk.com › products › diabetesExplore Diabetes Products

    Explore Diabetes Products. You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. This site is not country-specific and therefore may contain ...

  4. Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

  5. The Novo Nordisk Patient Assistance Program (PAP) is based on our commitment to our patients. The Patient Assistance Program provides medication at no cost to those who qualify. Patients who are approved for the PAP may qualify to receive free medicine from Novo Nordisk. There is no registration charge or monthly fee for participating.

  6. Notes on specific products. * in the US approved under the brand name Xultophy® 100/3.6. ** in the US called NovoLog®. *** in the US spelt Novoeight®. **** in the US approved under the name of REBINYN®. Overview of our diabetes medications, obesity medication and also medicines within haemophilia, human growth hormone and hormone ...

  7. www.novonordisk.com › news-and-media › news-and-irNews Details - Novo Nordisk

    Jun 4, 2021 · Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information

  1. People also search for